The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles

PURPOSE: Relugolix is an oral gonadotropin‐releasing hormone antagonist (GnRHant), which was first introduced in 2019. This study investigated the effects of the conventional injectable GnRHant formulation and this new oral GnRHant formulation on controlled ovarian stimulation (COS) cycles. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiya, Shinnosuke, Tsuzuki‐Nakao, Tomoko, Asai, Yoshiko, Inoue, Tomoko, Morimoto, Yoshiharu, Okada, Hidetaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967300/
https://www.ncbi.nlm.nih.gov/pubmed/35386367
http://dx.doi.org/10.1002/rmb2.12448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967300/
https://www.ncbi.nlm.nih.gov/pubmed/35386367
http://dx.doi.org/10.1002/rmb2.12448

Ejemplares similares